DEADLINE UPDATED: EZ-BAA AOI #25: FASTx closing date for abstract submissions is now May 31, 2024. We’re still seeking proposals to support early-stage development of therapeutic platforms. Interested parties can submit requests for a pre-proposal market research call to FASTx@hhs.gov. Learn more: https://ow.ly/IemQ50QXK3W
Biomedical Advanced Research and Development Authority (BARDA)
Government Administration
Washington, District of Columbia 18,775 followers
Advancing countermeasures against 21st century health threats. Part of HHS/ASPR. https://medicalcountermeasures.gov
About us
The Biomedical Advanced Research and Development Authority (BARDA), a component of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services, was established to aid in securing our nation from chemical, biological, radiological, and nuclear (CBRN) threats, as well as from pandemic influenza (PI) and emerging infectious diseases (EID). BARDA enhances the nation's public health security and emergency preparedness by facilitating communication on innovative products and solutions between federal agencies and public stakeholders.
- Website
-
https://www.medicalcountermeasures.gov/
External link for Biomedical Advanced Research and Development Authority (BARDA)
- Industry
- Government Administration
- Company size
- 501-1,000 employees
- Headquarters
- Washington, District of Columbia
- Type
- Government Agency
- Founded
- 2006
Locations
-
Primary
400 7th St SW
Washington, District of Columbia 20024, US
Employees at Biomedical Advanced Research and Development Authority (BARDA)
-
Chris Houchens
-
Kim Sciarretta
Supervisory Biologist, Biomedical Advanced Research and Development Authority, Department of Health and Human Services
-
Ashley Cecere, M.S.
Special Assistant to the Director at Biomedical Advanced Research & Development Authority
-
Anna Wight ORourke
Senior Advisor - Clinical Research & Development for the Biomedical Advanced Research & Development Authority (BARDA)
Updates
-
Today, our partner CARB-X published their annual report that highlights continued efforts accelerating early-stage antibacterial candidates into clinical development to help fill strategic gaps in the antimicrobial resistance (AMR) medical countermeasures pipeline. The report showcases project milestones, new funding commitments, upcoming funding rounds, and Portfolio Acceleration Tools. As a founding funder of the CARB-X global accelerator, BARDA is dedicated to advancing novel and innovative medical countermeasures to help combat the threat of drug-resistant infections and increase the USG’s preparedness posture. To read more about the progress achieved by CARB-X developers over the past year, visit https://lnkd.in/e27JjCn Learn more about our partnership with CARB-X and how we are working together to address AMR: https://lnkd.in/dSW3vwvP
📣 PUBLISHED TODAY: CARB-X’s 2023 Annual Report is out! The report highlights key takeaways from the portfolio strategy review, funding round results, our work in low- and middle-income countries (LMICs), new CARB-X funders the Government of Canada and the Novo Nordisk Foundation as well as renewed funding from UK Health Security Agency and Bundesministerium für Bildung und Forschung. 2023 saw the close of CARB-X’s Omnibus Funding Round focused on three themes: oral therapeutics, vaccines for neonatal sepsis and gonorrhea products. CARB-X received 237 Expressions of Interest from 185 unique applicants around the world. Several trends emerged, including: 👉 Rapid diagnostics expanded during the COVID-19 pandemic, leaving product developers poised to capitalize on their investments by embracing new sample types and pathogens. 👉 Half of therapeutics applicants were in the hit-to-lead stage, reinforcing the evident dearth of oral therapeutics in the clinical and preclinical pipelines. 👉 CARB-X received Expressions of Interest from the vaccine community in response to the lack of vaccines in development for K. pneumoniae, Extraintestinal Pathogenic E. coli, S. aureus, A baumannii, and N. gonorrhoeae. “With a shared vision of a healthier future for all, we look forward to continuing our work with partners in the antibacterial innovation chain to close this gap and bring innovative tools to everyone who needs them,” said Kevin Outterson, Executive Director of CARB-X and Austin B. Fletcher Professor of Law at Boston University. 🔗 Read more: bit.ly/49YZjOx Thank you to our funders: Boston University School of Law Boston University Biomedical Advanced Research and Development Authority (BARDA) HHS Administration for Strategic Preparedness and Response National Institute of Allergy and Infectious Diseases (NIAID) Wellcome Trust UK Health Security Agency Department of Health and Social Care Bundesministerium für Bildung und Forschung Bill & Melinda Gates Foundation Government of Canada and Novo Nordisk Foundation
-
This National Minority Health Month, we’re highlighting the necessity for diversity in clinical trials. While approximately 40% of the U.S. population is made up of racial and ethnic minorities, they are often underrepresented in clinical trials. A key component of our Strategic Plan is to ensure underrepresented populations are included in clinical trials. One of the ways we’re enabling increased health equity and diversity in clinical trials is through our partnership with company like Acclinate, one of the BARDA and Johnson & Johnson Innovation – JLABS Blue Knight program portfolio companies. Acclinate is a digital health company working to improve health equity through predictive analytics technology and community engagement. They specialize in accessing and engaging communities of color so individuals can make informed health decisions and learn about clinical trial participation. Through Acclinate’s omnichannel platform, NOWINCLUDED, they provide education, resources, and research opportunities to community members.
-
This National Minority Health Month, we’re highlighting ways in which we can help advance health preparedness in communities and nationwide. Our Accelerator Network partners UEL and Gener8tor connect socially and economically disadvantaged startups that have promising innovative technologies to educational resources and stakeholders that can accelerate business and product development. In addition to supporting startup founders, the BARDA Accelerator Network partners run programming to support underrepresented founders, including the gBETA MedTech Black Founder Accelerator program. Over two cohorts supported by BARDA, the gBETA MedTech Black Founder Accelerator program has supported 10 companies, creating 45 jobs and raising $404k. To learn more and contact us, visit: https://ow.ly/gEHE50Rj3rJ
-
Are you currently developing a medical countermeasure, technology platform, or manufacturing capability and think it might align with our mission space? We want to hear from you – submit a TechWatch today! Benefits of TechWatch meetings include: ✔️ Receive feedback from USG experts ✔️ Hear strategies for addressing technical and regulatory challenges ✔️ Get insight on how your solution could fit within the government ✔️ Better prepare you for a formal proposal submission Request a meeting today and be part of One Million Acts of Science. To learn more and request a TechWatch meeting, visit: https://ow.ly/zkxe50RhfQ4
-
DEADLINE UPDATED: EZ-BAA AOI #25: FASTx closing date for abstract submissions is now May 31, 2024. We’re still seeking proposals to support early-stage development of therapeutic platforms. Interested parties can submit requests for a pre-proposal market research call to FASTx@hhs.gov. Learn more: https://ow.ly/IemQ50QXK3W
-
Have you registered yet for the Blue Knight Symposium we’re hosting with Johnson & Johnson Innovation – JLABS? Join us on June 2 in San Diego to connect with global preparedness leaders and next generation innovators. Register today: https://jji.jnj/3woPmf6
-
We are encouraging the next generation of the STEM workforce through our SPRINT program, which partners with local schools in D.C., Maryland, and Virginia to engage students on scientific topics encompassed in BARDA’s mission, encourages students to consider a career in STEM and public service, and aims to generate excitement about BARDA's work in the biomedical and health security fields. Through SPRINT, students have access to educational programming, career advice, internships, mentorships and special events focused on STEM and civil service. This Citizen Science Month, learn how you can get involved and be part of One Million Acts of Science: https://ow.ly/Quhs50Rhf9b
-
BARDA joined industry partner Jubilant HollisterStier CMO for a ribbon cutting ceremony and a tour of their high-speed, commercial fill-finish line facility in Spokane, Washington. Filling and finishing vials are the last two steps in the manufacturing process for vaccines and therapeutics. During a pandemic or infectious disease outbreak, it is critical to ensure that the nation has enough domestic capacity to complete those final steps and make vaccines and therapeutics available. This project with Jubilant HollisterStier aims to enable faster production of vaccines in the U.S. when needed and to help bolster preparedness ahead of the next public health emergency. Learn more about how we’re making critical investments to foster and expand domestic pharmaceutical manufacturing: https://ow.ly/zvvY50Rfvsk